title: Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts.
abstract: Asthma is a chronic lung disease characterized by local inflammation that can result in structural alterations termed airway remodeling. One component of airway remodeling involves fibroblast accumulation and activation, resulting in deposition of collagen I around small bronchi. Prostaglandin E(2) (PGE(2)) is the main eicosanoid lipid mediator produced by lung fibroblasts, and it exerts diverse anti-fibrotic actions. Dysregulation of the PGE(2) synthesis/response axis has been identified in human pulmonary fibrotic diseases and implicated in the pathogenesis of animal models of lung parenchymal fibrosis. Here we investigated the relationship between the fibroblast PGE(2) axis and airway fibrosis in an animal model of chronic allergic asthma. Airway fibrosis increased progressively as the number of airway challenges with antigen increased from 3 to 7 to 12. Compared with cells from control lungs, fibroblasts grown from the lungs of asthmatic animals, regardless of challenge number, exhibited no defect in the ability of PGE(2) or its analogs to inhibit cellular proliferation and collagen I expression. This correlated with intact expression of the EP(2) receptor, which is pivotal for PGE(2) responsiveness. However, cytokine-induced upregulation of PGE(2) biosynthesis as well as expression of cyclooxygenase-2 (COX-2) and microsomal PGE synthase-1 declined with increasing numbers of antigen challenges. In addition, treatment with the COX-2-selective inhibitor nimesulide potentiated the degree of airway fibrosis following repeated allergen challenge. Because endogenous COX-2-derived PGE(2) acts as a brake on airway fibrosis, the inability of fibroblasts to upregulate PGE(2) generation in the inflammatory milieu presented by repeated allergen exposure could contribute to the airway remodeling and fibrosis observed in chronic asthma.
authors.affiliation: Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
authors.forename: Camila Leindecker
authors.initials: CL
authors.lastname: Stumm
authors.forename: Scott H
authors.initials: SH
authors.lastname: Wettlaufer
authors.forename: Sonia
authors.initials: S
authors.lastname: Jancar
authors.forename: Marc
authors.initials: M
authors.lastname: Peters-Golden
mesh_terms: D056151:Airway Remodeling / Q000187:drug effects; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D001249:Asthma / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism; D015232:Dinoprostone / Q000096:biosynthesis*; D004195:Disease Models, Animal; D015536:Down-Regulation; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D006651:Histocytochemistry; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D019746:Intramolecular Oxidoreductases / Q000096:biosynthesis; D051379:Mice; D000071876:Prostaglandin-E Synthases; D011658:Pulmonary Fibrosis / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D060888:Real-Time Polymerase Chain Reaction; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000485:Allergens; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D013449:Sulfonamides; D003094:Collagen; D051546:Cyclooxygenase 2; D019746:Intramolecular Oxidoreductases; C000605862:PTGES protein, human; D000071876:Prostaglandin-E Synthases; C000605865:Ptges protein, mouse; D015232:Dinoprostone; C012655:nimesulide